Amgen's Participation in the HealthCONx Conference
Amgen (NASDAQ: AMGN) is set to make a significant appearance at the annual Evercore ISI HealthCONx Conference, which will take place on December 3, 2025. The presentation is scheduled for 10:00 a.m. ET and will include insights from key executives within the company. Peter Griffith, the executive vice president and chief financial officer, alongside Jay Bradner, the executive vice president of Research and Development, will share their perspectives on Amgen's ongoing projects and strategies.
Webcast Availability
For those unable to attend in person, Amgen will provide a live webcast of the presentation. This resource will cater to media representatives, investors, and the general public alike, ensuring that key information is shared widely. The webcast will be easily accessible through Amgen’s official website, under the Investors section, and it will remain available for at least 90 days after the event for replay.
Innovative Medicines and Research
Amgen is renowned for its commitment to discovering, developing, manufacturing, and delivering innovative medicines aimed at combating some of the most challenging diseases faced by patients globally. With over 40 years of experience in the biotechnology sector, Amgen has established itself as a leader in advancing medical solutions through cutting-edge research and technology. The company utilizes human genetic data to push boundaries in medicine, working diligently to enhance its existing portfolio of treatments.
A Broad and Diverse Pipeline
Currently, Amgen is advancing a robust pipeline of therapies designed to treat various health conditions such as cancer, heart disease, osteoporosis, and numerous inflammatory and rare diseases. This strategic focus on innovation positions Amgen to make substantial contributions to the healthcare landscape, making a tangible impact on patient lives.
Recognition and Achievements
Recently, Amgen earned accolades as one of the "World's Most Innovative Companies" as well as one of "America's Best Large Employers" by prominent publications. Such achievements underline the company's commitment to quality, both in regards to its workforce and the groundbreaking work it conducts within the biotechnology field.
Market Presence and Position
Amgen holds a distinguished place in the financial markets as one of the key components of the Dow Jones Industrial Average and the Nasdaq-100 Index. These rankings highlight its significance within the market as a leader among innovative non-financial companies. The recognition further solidifies Amgen's position as a pivotal player in the biotechnology industry.
Staying Connected with Amgen
For further insights and updates about Amgen's activities, individuals can visit the official website and engage with the company through various social media platforms. Amgen maintains an active presence on X (formerly Twitter), LinkedIn, Instagram, YouTube, and Threads, providing regular updates and fostering connections with the public.
Contact Information
For media inquiries, Elissa Snook is reachable at 609-251-1407, while Casey Capparelli can be contacted at 805-447-1746 for investor-related questions. Amgen remains committed to transparency and communication with all stakeholders.
Frequently Asked Questions
What is the HealthCONx Conference?
The HealthCONx Conference is an annual event where industry leaders and companies share insights and advancements in healthcare and biotechnology.
Who will be presenting at Amgen's session?
Peter Griffith and Jay Bradner will represent Amgen at the conference, presenting on the company’s strategic developments.
How can I access the webcast of the presentation?
The webcast will be available on Amgen’s official website under the Investors section during and after the conference.
What has Amgen been recognized for recently?
Amgen was recognized as one of the "World's Most Innovative Companies" and as one of "America's Best Large Employers" for its contributions to biotechnology and its working environment.
How can I get in touch with Amgen for media inquiries?
Media inquiries can be directed to Elissa Snook at 609-251-1407 or Casey Capparelli at 805-447-1746 for investor questions.
